Glycosylation products as toxic mediators of diabetic complications.
Hyperglycemia causes excessive amounts of irreversible advanced glycosylation end products (AGEPs) to accumulate on long-lived extracellular matrix proteins and probably also on DNA in tissues that develop diabetic complications. AGEPs induce permanent abnormalities in extracellular protein cross-linking, cell-matrix interactions, and DNA structure in vitro. Pharmacologically inhibiting AGEP formation in long-term diabetic animals prevents both retinal capillary pathology and thickening of the glomerular basement membrane.
Brownlee
M
M
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.
D000818:Animals; D004247:DNA / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism*; D005109:Extracellular Matrix / Q000378:metabolism*; D006031:Glycosylation; D006943:Hyperglycemia / Q000378:metabolism*
D004247:DNA